Effects of the ghrelin receptor agonist anamorelin on lean body mass in cancer patients with cachexia; results from a Phase II randomized, double blind, multicenter study
نویسندگان
چکیده
Background Cancer anorexia-cachexia is a frequent, debilitating and life-threatening condition in which altered metabolism and reduced food intake contribute to weight loss (mainly due to lean body mass [LBM] loss), which cannot be reverted by conventional nutritional support. Safe/effective treatments for cancer cachexia remain an unmet need. The hunger hormone ghrelin has been shown to activate key pathways in the regulation of body composition. Anamorelin (ANAM) is a novel, selective, oral ghrelin receptor agonist with appetiteenhancing and anabolic activity. Anamorelin is currently being investigated in phase III studies for the treatment of anorexia-cachexia in advanced non-small cell lung cancer (also known as the ROMANA program).
منابع مشابه
Anamorelin (ONO‐7643) for the treatment of patients with non–small cell lung cancer and cachexia: Results from a randomized, double‐blind, placebo‐controlled, multicenter study of Japanese patients (ONO‐7643‐04)
BACKGROUND Cachexia, described as weight loss (mainly in lean body mass [LBM]) and anorexia, is common in patients with advanced cancer. This study examined the efficacy and safety of anamorelin (ONO-7643), a novel selective ghrelin receptor agonist, in Japanese cancer patients with cachexia. METHODS This double-blind clinical trial (ONO-7643-04) enrolled 174 patients with unresectable stage ...
متن کاملAnamorelin hydrochloride in the treatment of cancer anorexia–cachexia syndrome: design, development, and potential place in therapy
Anamorelin hydrochloride is an orally active ghrelin receptor agonist in development by Helsinn, for the treatment of non-small-cell lung cancer (NSCLC) cachexia. In preclinical and clinical studies, the potent affinity of anamorelin for the ghrelin receptor is associated with significant appetite-enhancing activity and resultant improvements in body weight, lean body mass, and handgrip strengt...
متن کاملNovel mechanism of ghrelin therapy for cachexia
I read with great interest the recent article by Ji-an Chen et al. Calorie intake is a major factor for the body composition including muscle mass. So, increase of food intake by the ghrelin administration in vivo could be one of the mechanisms for improvement of muscle wasting. In addition to that, this article showed the novel mechanism, which suggested that ghrelin administration could impro...
متن کاملROMANA 3: a phase 3 safety extension study of anamorelin in advanced non-small-cell lung cancer (NSCLC) patients with cachexia
Background Cancer anorexia-cachexia is a debilitating condition frequently observed in NSCLC patients, characterized by decreased body weight, reduced food intake, and impaired quality of life. Anamorelin, a novel selective ghrelin receptor agonist, has anabolic and appetite-enhancing activities. Patients and methods ROMANA 3 was a safety extension study of two phase 3, double-blind studies t...
متن کاملThe Potential of Ghrelin in Cancer Anorexia–Cachexia
© Touch MEdical MEdia 2013 77 Abstract The cancer anorexia–cachexia syndrome (CACS) is often seen in patients with incurable malignancies and is associated with increased mortality, decreased efficacy of anticancer treatments and poor quality of life. However, there are currently no effective therapies for CACS. Since CACS is a multifactorial syndrome with a complex pathophysiology, therapeutic...
متن کامل